RNA

Prosensa Holding N.V. Press Releases

$18.82
*  
0.06
0.32%
Get RNA Alerts
*Delayed - data as of Dec. 26, 2014  -  Find a broker to begin trading RNA now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
BioMarin and Prosensa Announce Expiration of the Hart-Scott-Rodino Waiting Period for BioMarin''s Proposed Acquisition of Prosensa
12/24/2014 1:15:00 PM - GlobeNewswire


PROSENSA HOLDING N.V. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
12/12/2014 12:40:00 PM - PR Newswire


Prosensa Wins Scrip ''Biotech Company of the Year'' 2014 Award
12/8/2014 8:00:00 AM - GlobeNewswire


Prosensa Holding N.V. Acquisition By BioMarin Pharmaceutical Inc. May Not Be In The Best Interests of RNA Shareholders
12/3/2014 4:11:00 PM - PR Newswire
▼-0.74 % Price Change since this news event. The Volume Ratio is 1.98.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Prosensa Holding N.V. (RNA) Over the Proposed Sale of the Company to BioMarin Pharmaceutical Inc.
11/25/2014 7:00:00 PM - Business Wire


PROSENSA SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Believe the Acquisition by BioMarin May be Unfair to Shareholders
11/24/2014 11:33:00 AM - Business Wire


BioMarin and Prosensa Holding N.V. Reach Agreement on Intended Public Offer for 100% of Prosensa's Outstanding Stock; Will Add Duchenne Muscular Dystrophy Products to Rare-Disease Portfolio
11/24/2014 6:00:00 AM - GlobeNewswire


Prosensa Announces 3rd Quarter 2014 Financial Results and Recent Corporate Developments
11/17/2014 7:00:00 AM - GlobeNewswire


Cure Duchenne and Prosensa to Present Collaboration at Partnering for Cures Conference
11/12/2014 3:02:00 PM - Business Wire
▲61.68 % Price Change since this news event. The Volume Ratio is 0.57.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Prosensa Holding N.V. to Webcast Conference Call Discussing 3rd Quarter 2014 Financial Results and Corporate Update on November 17, 2014
11/10/2014 8:00:00 AM - GlobeNewswire


Prosensa to Present at Upcoming Investor Conferences
11/7/2014 10:56:00 AM - GlobeNewswire


Prosensa begins NDA submission to the FDA for exon-skipping drug drisapersen to treat Duchenne muscular dystrophy
10/10/2014 10:10:00 AM - GlobeNewswire